Eleftha 440 mg Injection contains Trastuzumab, a recombinant humanized monoclonal antibody used in targeted cancer therapy. It is specifically designed to treat cancers that overexpress the HER2 (Human Epidermal Growth Factor Receptor 2) protein. Trastuzumab plays a crucial role in improving survival outcomes in HER2-positive cancers.
Mechanism of Action
Trastuzumab works by:
- Binding selectively to the HER2 receptors on cancer cells
- Inhibiting HER2-mediated signaling pathways responsible for tumor growth
- Inducing antibody-dependent cellular cytotoxicity (ADCC), helping the immune system destroy cancer cells
- Preventing uncontrolled cell proliferation
This targeted approach allows it to specifically attack cancer cells while limiting damage to normal cells.
Uses
Eleftha 440 mg Injection is indicated for:
- HER2-positive Breast Cancer (early-stage and metastatic)
- HER2-positive Metastatic Gastric Cancer
It is often used alone or in combination with chemotherapy.
Adverse Effects
Common Side Effects:
- Fever and chills (especially during infusion)
- Nausea and vomiting
- Fatigue
- Diarrhea
Serious Side Effects:
- Cardiotoxicity (reduced heart function, heart failure)
- Infusion-related reactions (shortness of breath, hypotension)
- Pulmonary toxicity
- Risk of infections
Reviews
There are no reviews yet.